옵션 체인은 다양한 행사가격과 만기일에 대한 Dr Reddy's Laboratories의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Dr Reddy's Laboratories에 대한 시장 심리를 평가합니다..

Dr Reddy's Laboratories (NYSE:RDY) 주식, 옵션 체인

Dr Reddy's Laboratories

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Large Cap

News

Movers

Trading Ideas

BIRK

CHWY

DOCS

KVYO

NBIX

TEVA

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 테바 파마수티컬스(NYSE:TEVA)의 주식은 회사와 사노피 SA(NASDAQ:SNY)가 궤양성 대장염 및 크론병에 대한 두바키투그(Duvakitug)의 2b상 시험에서 1차 평가변수가 충족되었다고 발표한 후 주가는 33.88% 상승했다.

테바, 리 오토 및 다덴 레스토랑이 지난주 최고 성과를 보여준 10개 대형주 중 일부 (12월 16-20일)

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories Ltd

Newpath Resources Inc

<h3>Companies Reporting Before The Bell</h3>
• Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) is estimated to report quarterly earnings at $3.86 per share on revenue of $44.72 billion. 
• Chunghwa Telecom (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHT#NYSE">CHT</a>) is projected to report earnings for its fourth quarter. 
• WNS (Hldgs) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WNS#NYSE">WNS</a>) is likely to report quarterly earnings at $1.04 per share on revenue of $332.22 million. 
• Pacific Premier Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPBI#NASDAQ">PPBI</a>) is likely to report quarterly earnings at $0.31 per share on revenue of $142.92 million. 
• OSI Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSIS#NASDAQ">OSIS</a>) is expected to report quarterly earnings at $2.33 per share on revenue of $406.61 million. 
• Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) is expected to report quarterly earnings at $2.78 per share on revenue of $6.15 billion. 
• Texas Capital Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBI#NASDAQ">TCBI</a>) is projected to report quarterly earnings at $1.08 per share on revenue of $283.78 million. 
• Old Republic Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORI#NYSE">ORI</a>) is projected to report quarterly earnings at $0.69 per share on revenue of $2.11 billion. 
• West Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTBA#NASDAQ">WTBA</a>) is expected to report quarterly earnings at $0.40 per share on revenue of $21.42 million. 
• Valley Ntl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLY#NASDAQ">VLY</a>) is estimated to report quarterly earnings at $0.14 per share on revenue of $467.97 million. 
• MarineMax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HZO#NYSE">HZO</a>) is projected to report quarterly loss at $0.18 per share on revenue of $485.52 million. 
• First BanCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBP#NYSE">FBP</a>) is likely to report quarterly earnings at $0.41 per share on revenue of $236.55 million. 
• Novagold Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NG#AMEX">NG</a>) is estimated to report earnings for its fourth quarter. 
• Northern Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRS#NASDAQ">NTRS</a>) is estimated to report quarterly earnings at $2.00 per share on revenue of $1.93 billion. 
• Dr Reddy's Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>) is estimated to report quarterly earnings at $0.19 per share on revenue of $964.48 million. 
• Amalgamated Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAL#NASDAQ">AMAL</a>) is estimated to report quarterly earnings at $0.87 per share on revenue of $81.90 million. 
• MakeMyTrip (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) is likely to report quarterly earnings at $0.45 per share on revenue of $264.99 million. 
• Heritage Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HFWA#NASDAQ">HFWA</a>) is expected to report quarterly earnings at $0.44 per share on revenue of $60.71 million. 
• Dime Community Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCOM#NASDAQ">DCOM</a>) is likely to report quarterly earnings at $0.45 per share on revenue of $62.64 million. 
• McCormick &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MKC#NYSE">MKC</a>) is expected to report quarterly earnings at $0.77 per share on revenue of $1.77 billion. 
• American Airlines Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) is projected to report quarterly earnings at $0.39 per share on revenue of $13.13 billion. 
• TAL Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAL#NYSE">TAL</a>) is expected to report quarterly earnings at $0.06 per share on revenue of $539.86 million. 
• Global X Guru Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GURU#NYSE">GURU</a>) is projected to report quarterly loss at $0.09 per share on revenue of $7.55 million. 
• LSI Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYTS#NASDAQ">LYTS</a>) is estimated to report quarterly earnings at $0.20 per share on revenue of $129.20 million. 
• GATX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GATX#NYSE">GATX</a>) is likely to report quarterly earnings at $1.78 per share on revenue of $399.00 million. 
• Independent Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBCP#NASDAQ">IBCP</a>) is estimated to report quarterly earnings at $0.76 per share on revenue of $48.94 million. 
• Freeport-McMoRan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) is projected to report quarterly earnings at $0.35 per share on revenue of $6.27 billion. 
• Banc of California (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BANC#NYSE">BANC</a>) is expected to report quarterly earnings at $0.23 per share on revenue of $272.18 million. 
• GE Aero (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) is likely to report quarterly earnings at $1.05 per share on revenue of $9.84 billion. 
• Atlantic Union Bankshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AUB#NYSE">AUB</a>) is estimated to report quarterly earnings at $0.79 per share on revenue of $222.26 million. 
<h3>Companies Reporting After The Bell</h3>
• Texas Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) is projected to report quarterly earnings at $1.20 per share on revenue of $3.87 billion. 
• Covenant Logistics Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVLG#NYSE">CVLG</a>) is expected to report quarterly earnings at $0.50 per share on revenue of $284.91 million. 
• OceanFirst Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCFC#NASDAQ">OCFC</a>) is projected to report quarterly earnings at $0.36 per share on revenue of $94.95 million. 
• First Western Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYFW#NASDAQ">MYFW</a>) is expected to report quarterly earnings at $0.26 per share on revenue of $24.41 million. 
• SouthState (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSB#NYSE">SSB</a>) is expected to report quarterly earnings at $1.73 per share on revenue of $434.57 million. 
• Five Point Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FPH#NYSE">FPH</a>) is likely to report earnings for its fourth quarter. 
• USCB Financial Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USCB#NASDAQ">USCB</a>) is expected to report quarterly earnings at $0.37 per share on revenue of $22.41 million. 
• First Financial Bancor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFBC#NASDAQ">FFBC</a>) is projected to report quarterly earnings at $0.65 per share on revenue of $216.32 million. 
• First Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRBA#NASDAQ">FRBA</a>) is estimated to report quarterly earnings at $0.39 per share on revenue of $32.84 million. 
• SLM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLM#NASDAQ">SLM</a>) is expected to report quarterly earnings at $0.56 per share on revenue of $371.74 million. 
• MidWestOne Financial Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOFG#NASDAQ">MOFG</a>) is estimated to report quarterly earnings at $0.72 per share on revenue of $57.00 million. 
• Midland States Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSBI#NASDAQ">MSBI</a>) is likely to report quarterly earnings at $0.67 per share on revenue of $73.57 million. 
• Metropolitan Bank Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCB#NYSE">MCB</a>) is estimated to report quarterly earnings at $1.49 per share on revenue of $67.43 million. 
• Customers Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUBI#NYSE">CUBI</a>) is estimated to report quarterly earnings at $1.20 per share on revenue of $164.07 million. 
• East West Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWBC#NASDAQ">EWBC</a>) is expected to report quarterly earnings at $2.12 per share on revenue of $659.00 million. 
• Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) is estimated to report quarterly earnings at $1.75 per share on revenue of $2.20 billion. 
• Glacier Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBCI#NYSE">GBCI</a>) is projected to report quarterly earnings at $0.52 per share on revenue of $224.99 million. 
• Business First Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFST#NASDAQ">BFST</a>) is likely to report quarterly earnings at $0.49 per share on revenue of $75.13 million. 
• SB Finl Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFG#NASDAQ">SBFG</a>) is expected to report quarterly earnings at $0.41 per share on revenue of $10.20 million. 
• Byline Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BY#NYSE">BY</a>) is projected to report quarterly earnings at $0.61 per share on revenue of $100.39 million. 
• Eastern Bankshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBC#NASDAQ">EBC</a>) is projected to report quarterly earnings at $0.34 per share on revenue of $184.71 million. 
• 1st Source (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRCE#NASDAQ">SRCE</a>) is likely to report quarterly earnings at $1.33 per share on revenue of $97.65 million. 
• Associated Banc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASB#NYSE">ASB</a>) is likely to report quarterly earnings at $0.52 per share on revenue of $337.81 million. 
• Columbia Banking System (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLB#NASDAQ">COLB</a>) is projected to report quarterly earnings at $0.66 per share on revenue of $489.74 million. 
• CSX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>) is likely to report quarterly earnings at $0.44 per share on revenue of $3.61 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

AMAL

BANC

BFST

COLB

CUBI

CVLG

DCOM

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

EWBC

FFBC

FRBA

GATX

GBCI

GURU

HFWA

IBCP

ISRG

LYTS

MMYT

MOFG

MSBI

MYFW

NTRS

OCFC

OSIS

PPBI

SBFG

SRCE

TCBI

USCB

WTBA

Earnings Scheduled For January 23, 2025

CVS Health Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) subsidiary, Aetna Inc., has filed a lawsuit against more than 20 generic drug manufacturers. The lawsuit alleges a coordinated scheme to fix prices, <a href="https://www.benzinga.com/topic/drug-prices">allocate markets, and stifle competition</a>.
The result was a significant overcharge for essential medications.
Defendants include Teva Pharmaceutical Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), Amneal Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRX#NASDAQ">AMRX</a>), Dr. Reddy&#8217;s Laboratories Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>), Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>), Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), Viatris, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>), among others.
The <a target="_blank" href="https://civilinquiry.jud.ct.gov/DocumentInquiry/DocumentInquiry.aspx?DocumentNo=29056426" rel="noreferrer noopener">lawsuit</a> accuses the defendants of orchestrating one of the largest price-fixing conspiracies in U.S. history, causing inflated drug prices and widespread harm to consumers, insurers, and the healthcare system.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42600472/your-healthcare-costs-are-soaring-us-spending-reached-5-trillion-in-2023-with-major-increase-in-obesity-and-diabetes-drugs-hospital-services" rel="noreferrer noopener">Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services</a>
The lawsuit claims that these pharmaceutical companies colluded to artificially raise generic drug prices by as much as 2,762%.
Examples include clomipramine (2,600% increase), nadolol (+2,762%), and oxybutynin chloride (up to 1,500%).
Aetna alleges this conspiracy exploited market conditions, fostered cronyism, and suppressed competition, while depriving third-party payers like Aetna of expected cost savings.
According to the complaint, the defendants utilized secretive methods to implement their price-fixing strategies. These included in-person meetings, private phone calls, and strategic coordination during trade association events. Evidence of collusion was deliberately minimized, with written communications often destroyed to evade detection.
Central to the allegations is the so-called &#8220;fair share&#8221; system, which allocated market share and dictated price increases among competitors. This strategy, referred to as the &#8220;rules of engagement,&#8221; ensured that generic drugmakers avoided undercutting one another, thereby maintaining inflated prices. In some cases, competitors allegedly submitted cover bids to maintain an artificial equilibrium in the market.
The lawsuit highlights Teva Pharmaceuticals as an example of this practice, alleging the company collaborated with select &#8220;high-quality&#8221; competitors to lead and follow each other&#8217;s price hikes.
This agreement reportedly extended to various drugs, enabling the companies to dominate the market and secure extraordinary profits.
Aetna contends that the defendants&#8217; actions have severely impacted the U.S. healthcare system, driving up costs for insurers, consumers, and government programs like Medicare Part D.
The insurer is seeking treble damages and injunctive relief under state antitrust and unfair competition laws to recover losses and prevent future anticompetitive practices.
Price Action: CVS stock is up 2.31% at $46.85 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42813560/extended-pfizers-antiviral-paxlovid-use-shows-mixed-results-for-long-covid-relief-study" target="_blank" rel="noreferrer noopener">Pfizer Antiviral Paxlovid&#8217;s Extended Use Shows Mixed Results for Long COVID Relief: Study</a></li>
</ul>
Image: Shutterstock

Health Care

Legal

General

AMRX

VTRS

CVS Health's Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Prices

<a href="https://www.bseindia.com/xml-data/corpfiling/AttachLive/79ff5f5f-81a0-4bb0-a2f0-b93541f1164e.pdf" title="https://www.bseindia.com/xml-data/corpfiling/AttachLive/79ff5f5f-81a0-4bb0-a2f0-b93541f1164e.pdf">https://www.bseindia.com/xml-data/corpfiling/AttachLive/79ff5f5f-81a0-4bb0-a2f0-b93541f1164e.pdf</a>

Global

Dr. Reddy's Laboratories Forms New Subsidiary In Finland, 'Dr. Reddy's Finland Oy', As Step-Down Wholly-Owned Entity

These ten large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Teva Pharmaceutical Industries Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) stock escalated 33.88% after the company and Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) announced that primary endpoints were met in the Phase 2b trial of Duvakitug for <a href="https://www.benzinga.com//node/42531132" target="_blank" rel="noreferrer noopener">ulcerative colitis and Crohn&#8217;s disease</a>.</li>
<li>Klaviyo, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>) shares surged 12.85%.</li>
<li>Olive Garden parent Darden Restaurants, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) stock rose 12.54% after the company reported better-than-expected second-quarter EPS and <a href="https://www.benzinga.com//node/42585797" target="_blank" rel="noreferrer noopener">issued an FY25 revenue outlook</a>. Several analysts raised the <a href="https://www.benzinga.com/quote/dri/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast on the stock</a>.</li>
<li>Doximity, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) shares upped 10.91%. Stephens &amp; Co. initiated coverage with an Equal-Weight rating and <a href="https://www.benzinga.com/quote/docs/analyst-ratings" target="_blank" rel="noreferrer noopener">a price forecast of $55</a>.</li>
<li>Birkenstock Holding plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>) shares increased 9.70% after the company reported better-than-expected fourth-quarter financial results and issued FY25 guidance. Several analysts raised <a href="https://www.benzinga.com//node/42599431" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>Jabil Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) stock upped 7.30% after the company reported better-than-expected <a href="https://www.benzinga.com//node/42553094" target="_blank" rel="noreferrer noopener">first-quarter EPS and revenues</a>. Several analysts raised <a href="https://www.benzinga.com/quote/jbl/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>Neurocrine Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) stock rose 6.88%. The FDA approved Crenessity (crinecerfont) capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with <a href="https://www.benzinga.com//node/42508449" target="_blank" rel="noreferrer noopener">classic congenital adrenal hyperplasia (CAH).</a></li>
<li>GameStop Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) stock was up 6.54% last week, continuing strength from Q3 earnings.</li>
<li>Dr. Reddy&#8217;s Laboratories Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>) stock increased 6.29%.</li>
<li>Li Auto Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) shares upped 6.13% last week.</li>
</ol>
Photo by Sundry Photography via Shutterstock

Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?

<ul>
<li>Only immuno-oncology drug approved by various regulatory authorities around the world such as the USFDA, DCGI, EMA, MHRA, NMPA and others for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC)</li>
<li>Combination of Toripalimab and standard of care chemotherapy has shown a 48% reduction in risk of progression or death</li>
<li>Launched in India in the same year as its launch in the U.S., making India the third country in the world to receive access to this New Biological Entity (NBE)</li>
</ul>

Reported Thursday, Dr. Reddy's Introduces Toripalimab In India, Immuno-Oncology Drug Approved For The Treatment Of Nasopharyngeal Carcinoma

Dr. Reddy's Laboratories, Inc. and Senores Pharmaceuticals, Inc. today announced the launch of Ivermectin Tablets USP, 3 mg, which is bioequivalent and therapeutically equivalent to STROMECTOL&#xAE; Tablets of Merck Sharp and Dohme LLC in the U.S. market. The product will be marketed by Dr. Reddy's.

Dr. Reddy's Laboratories, Senores Pharmaceuticals Launch Ivermectin Tablets USP, 3 mg In US Market

Dear Fellow Stockholder,
Given my recent transition to the role of CEO, I wanted to share my thoughts on Coya and our future and to express my gratitude to our founder and Executive Chair, Dr. Howard Berman, whose bold vision has instilled the "innovation and get-it-done" culture in Coya's DNA. We have made tremendous strides in 2024, repeatedly executing on our promises. As I look to 2025, I am confident that our nimble and highly experienced team will continue to exceed expectations.
I have spent my entire 25-year career in the biotech space, and I believe that Coya has the most promise of any company that I have represented. I truly believe our novel science, strong clinical proof of concept data, pharmaceutical partnership validation, cash runway, and clear path to a commercial drug differentiates us. Prior to serving at Coya, I helped spearhead and lead pharmaceutical transactions worth billions of dollars that led to significant value creation. I believe the opportunities ahead of us in 2025 and beyond are what investors, stockholders, and patients should be most excited about. Our science and approach of regulating Tregs is now validated in multiple trials across multiple neurodegenerative diseases, we have a track record of executing value-creating non-dilutive deals, and our strong cash position allows us to be prudent in our decisions.
Year Ahead
We expect our activities in 2025 to be focused on the following indications:
ALS (Amyotrophic Lateral Sclerosis) Program: We have alignment with the FDA on the data required to initiate our potentially pivotal COYA 302 Phase 2 double-blind randomized study in patients with ALS. We are targeting the submission of the requested data package by 2Q 2025 and initiation of the clinical trial upon FDA clearance. The roadmap to topline results is now clear with reduced uncertainty. In late 2023, we partnered with Dr. Reddy's Laboratories, a multi-billion-dollar drug developer, to license COYA 302 in ALS in a deal that is worth up to $700 million. We still retain the rights to COYA 302 in ALS in Japan and South/Central America and Mexico, thus providing us direct upside and optionality in this indication alone.
FTD (Frontotemporal Dementia) Program: We expect to see topline results in 2H 2025 from the investigator-initiated, open-label study of Low Dose IL-2 (LD IL-2) + CTLA4-Ig in FTD. Study endpoints will measure safety, peripheral and central inflammation, FTD progression, and pharmacodynamic effects on Treg cell populations. The data are expected to guide our planned COYA 302 Phase 2 double-blind randomized study (which will be funded by the Alzheimer's Drug Discovery Foundation) and further optimize the design for success. The guidance from the FDA on the ALS IND reduces uncertainty on the planned IND filing for FTD in 2H of 2025. We have retained full commercial rights on this program thus far, providing us optionality to develop the program to BLA approval ourselves and capture the full potential upside or partner at a later stage once we obtain additional clinical data.
AD (Alzheimer's disease) Program: Complementing the promising data that was presented at CTAD in Madrid for LD IL-2 in mild to moderate AD, the investigators will disclose additional data in 1H 2025 that summarizes the changes in inflammation in the peripheral system (blood) and central nervous system (CSF and brain) and other molecular measurements for the two IL-2 dosing arms vs. placebo. These important data will help to further address the basic science associated with the promising clinical response observed in the lower dose IL-2 arm and its association with better Treg enhancement. We retain full rights to the AD indication for COYA 302 and are already in the process of exploring non-dilutive and strategic partnering opportunities. While the CTAD data was based on LD IL-2 alone and proved highly promising in and of itself, COYA 302, which is a proprietary combination of LD IL-2 and CTLA4-Ig, targets multiple pathways and is developed to more significantly and durably enhance Treg function, which we believe will be highly attractive to potential partners.
Strategic Partnerships
Dr. Reddy's Partnership: Our partnership with Dr. Reddy's Laboratories is approaching its one-year anniversary, and our collaboration could not be stronger. We have a reliable partner for ALS, and leveraging its resources and expertise has created value beyond the milestone payments. In 2025, we anticipate receiving $8.4 million upon initiation of the Phase 2 ALS clinical trial and will continue to evaluate opportunities to further deepen the relationship.
Other Strategic Possibilities: As I have described, my background is one of deal-making, and I intend to leverage my network and capabilities to maximize opportunities for Coya in 2025. We have only partnered COYA 302 in ALS, and the optionality to partner, co-develop, or license the asset in other indications exists. Any potential transaction will be evaluated based on maximizing stockholder value. The positive data from the investigator-initiated trial of LD IL-2 in patients with Alzheimer's disease increases our confidence in obtaining value-creating pharma partnerships that combine our proprietary LD IL-2, COYA 301, with other modalities. I can envision multiple opportunities with LD IL-2 serving as a backbone adjuvant with standard of care agents and other novel pathways.
Moreover, the opportunity for grant funding and financial support from foundations exists and will be vigorously pursued. We believe the data emerging on Tregs in autoimmune disease (such as lupus, rheumatoid arthritis, and scleroderma) and, in particular, treatment with LD IL-2 is compelling and may strengthen the role of COYA 302 and LD IL-2 combinations in this space. I intend to actively pursue partnerships in this arena that would further place us in a strong position to pursue value-creating deals.
Value-Creating Pipeline
Like many experts in the scientific community, we believe combination strategies are the future to address devastating neurodegenerative diseases. We believe targeting one mechanism or pathway is likely insufficient to achieve maximal effect - hence our approach with COYA 302. COYA 302 is a "Pipeline within a Product" and has strong potential in ALS, FTD, AD, Parkinson's disease, and other indications.
We are continuously building our intellectual property to further enhance the value of Coya. One recent development is the combination of COYA 301 and GLP-1 agonists. Data suggests that the mechanism of action appears additive and/or synergistic in ameliorating inflammation. This is yet another opportunity for value-creating strategic partnerships. We intend to publish more detailed data in 1Q 2025.
Conclusion
As you can see from our past performance, our entire management team is committed to the success of Coya. We expect to recognize a number of clinical, regulatory, and/or commercial milestones in 2025 that will help us advance the treatment of neurodegenerative diseases.
On behalf of the entire Coya team, please accept our sincere gratitude for both your support and belief in our science, our story, and our team. We look forward to presenting additional clinical data and updating you on our additional corporate developments as they unfold. Onwards and upwards!

COYA

Coya Therapeutics Highlights Strategic Vision Under New CEO, With Key 2025 Milestones Including ALS Trial With Dr. Reddy's Partnership Worth Up To $700M, Emerging Opportunities In Parkinson's And Autoimmune Conditions, And Focus On Non-Dilutive Funding To Advance Treg-Enhancing Biologics For Neurodegenerative And Autoimmune Diseases

Dr. Reddy&#8217;s Laboratories Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>) reported Tuesday a second-quarter 2025 net income of $160 million, down from $177 million a year ago.
Revenue increased from $821 million to $957 million — almost a 16.6% jump.
The strong revenue growth during the quarter was <a target="_blank" href="https://www.drreddys.com/cms/cms/sites/default/files/2024-11/Q2%20FY25%20Results%20.pdf" rel="noreferrer noopener">primarily</a> driven by growth in global generics revenues. The sequential growth was led by global generics revenues in Emerging Markets, India, Europe and Pharmaceutical Services and Active Ingredients (PSAI).
EBITDA for the quarter rose from $260 million to $272 million.
&#8220;We delivered another good quarter and maintained the growth momentum across businesses. We made progress on our future growth drivers, operationalized our venture with Nestle and completed the acquisition of Nicotinell and related brands,&#8221; said co-chair GV Prasad.
Global generics revenues during the second quarter reached 71.6 billion rupees, showing a 17% year-over-year growth, driven by improved sales volumes and new product launches.
North American sales increased 17% (a sequential decline of 3%) to 37.3 billion rupees. YoY growth was largely due to increased sales volumes, partly offset by price erosion. The sequential decline was due to a decrease in sales volumes.
Gross Margin at 59.6% (GG: 63.1 %, PSAI: 30.0%), a YoY increase of 92 basis points (bps) and a QoQ decline of 81 bps. The YoY increase was due to an improvement in product mix and overhead leverage, partly offset by price erosion. On a sequential basis, the decline was primarily due to changes in the mix.
Price Action: Dr. Reddy&#8217;s Laboratories is up 4.81% at $15.51 during the premarket session at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41745824/short-squeeze-globalfoundries-stock-soars-on-q3-earnings-beat-strong-q4-outlook" target="_blank" rel="noreferrer noopener">Short Squeeze &#8211; GlobalFoundries Stock Soars On Q3 Earnings Beat, Strong Q4 Outlook</a></li>
</ul>

Dr. Reddy's Lab Delivers 'Another Good Quarter,' CEO Says As Revenue Jumps 17%

Dr. Reddy's Laboratories shares are trading higher after the company reported a year-over-year increase in Q2 sales results.

Dr Reddy's Laboratories Q2 2025 GAAP EPS $0.18 Compared To $0.21 YoY, Sales $957.00M Compared To $821M YoY

Aurigene Oncology Limited, a wholly-owned subsidiary of Dr. Reddy's Laboratories Limited and a clinical stage biotech committed to bringing in novel and effective therapeutics for the treatment of cancer, has announced the Phase 1 results for Ribrecabtagene autoleucel (DRL-1801) from the SWASTH study – India's first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma. The study reported initial results from the first 8 patients. All patients were heavily pre-treated with median of 5.5 previous lines of treatment. Most patients had also received transplant in the past and had disease progression post-transplant. All 8 patients (100%) achieved clinical response, with 5/8 (62.5%) having achieved stringent complete response. With respect to safety, there were no high-grade events of Cytokine Release Syndrome (CRS) or neurotoxicity, in any of the patients.

Dr. Reddy's Subsidiary Aurigene Oncology, Announced Phase 1 Results For Ribrecabtagene Autoleucel From SWASTH Study; All 8 Patients Achieved Clinical Response

Dr. Reddy&#39;s Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:<a href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as &quot;Dr. Reddy&#39;s&quot;)), today announced that it has entered into a royalty-free non-exclusive voluntary licensing agreement with Gilead Sciences Ireland UC for the manufacture and commercialisation of the drug, Lenacapavir, in India and 120 other countries.
Lenacapavir is a United States Food and Drug Administration (USFDA) approved drug indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations. Additionally, Lenacapavir is currently under investigation for the prevention of HIV (PrEP) which is yet to be approved globally.
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca&reg; in the United States and Europe markets in the year 2022. It is a first-in-class HIV-1 capsid inhibitor.
Dr. Reddy&#39;s has been granted a non-exclusive voluntary licence to manufacture Lenacapavir and market it in 120 countries, for the current approved indication of HIV treatment in heavily treatment-experienced (HTE) adults with multi-drug resistant HIV. Dr. Reddy&#39;s will be responsible for technology transfer at its manufacturing site, conducting bioequivalence/clinical studies, product registration and launch in the agreed markets. Additionally, the agreement grants licence to Dr. Reddy&#39;s to manufacture and commercialise lenacapavir for the indication of prevention of HIV (PrEP) in 120 countries, if approved.

Biotech

GILD

Dr. Reddy's Signs Voluntary Licensing Agreement With Gilead Sciences To Manufacture And Commercialise Lenacapavir In India And Other Countries

Pending further discussions with Dr. Reddy's Laboratories SA, a subsidiary of Dr. Reddy's Laboratories, Ltd. (collectively, "Dr. Reddy's"), Dr. Reddy's agreed to a partial deferral without penalty of a milestone payment by Citius Oncology, Inc. (the "Company"), which was triggered upon regulatory approval of LYMPHIRTM by the U.S. Food and Drug Administration and due on September 9, 2024, pursuant to the terms of the Asset Purchase Agreement, dated as of September 1, 2021, between Dr. Reddy's and Citius Pharmaceuticals, Inc. (the "Asset Purchase Agreement").

Contracts

CTOR

Dr. Reddy's Laboratories Agreed To Partially Defer A Milestone Payment From Citius Oncology, Inc., Due On September 9, 2024, Upon FDA Approval Of  LYMPHIR, Without Penalty, Pending Further Discussions, As Per Their 2021 Asset Purchase Agreement

Dr. Reddy's Issues Clarification Regarding Allegations Tied To Engagement With Agora Advisory; Confirms Engagement Of Dhaval Buch From October 2020 To April 2021, Prior To Madhabi Buch's SEBI Chairpersonship; Asserts Compliance With Laws And Denies Any Preferential Treatment By SEBI

Dr. Reddy's Receives FDA Form 483 With Three Observations Following Inspection At Srikakulam Facility

<ul>
<li>Malaria is a life-threatening public health issue, particularly in low- and middle-income countries. There is a need for an effective, affordable, and accessible preventive and/or treatment medication. This potential partnership is a step towards this cause</li>
<li>This potential partnership aims to bring together Kainomyx's expertise in novel drug discovery, Aurigene's capability to conduct integrated drug discovery and development, and Dr. Reddy's ability to commercialize products in low and middle-income countries, in addition to the US and Europe</li>
<li>It is a testament to the commitment of involved parties towards promoting global public health and Dr. Reddy's goal of reaching 1.5 billion patients by 2030</li>
</ul>
Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:<a href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's")), and its CRDMO arm Aurigene Pharmaceutical Services Limited (Aurigene), today announced that they have signed a non-binding Memorandum of Understanding (MoU) with Kainomyx, Inc., a US-based company with a proprietary platform that helps target cytoskeletal proteins of parasites, a novel mechanism of action, for the development and commercialization of affordable anti-malarial drug in the U.S., Europe, and in low and middle-income countries. The MoU remains subject to signing of a definitive agreement.

Dr. Reddy's Laboratories, Aurigene Pharmaceutical Services, And Kainomyx Sign Non-Binding MoU For Joint Development Of Affordable Anti-Malarial Drug

Barclays analyst Balaji Prasad maintains Dr Reddy's Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>) with a Overweight and raises the price target from $81 to $87.

Price Target

Analyst Ratings

Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $87

Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:<a href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's")), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the launch of its proposed biosimilar Rituximab candidate DRL_RI (ITUXREDI&#xAE;) in European markets.
Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance and drug product manufacturing facility located in Hyderabad, India. As part of the established approval process, the CHMP positive opinion will now be reviewed by the European Commission (EC), following which a decision will be made on the grant of marketing authorisation in the European Union (EU) member countries, and the European Economic Area (EEA) member states of Norway, Iceland, and Liechtenstein. A Marketing Authorisation Application (MAA) for submission to the UK Medicines and Healthcare products Regulatory Agency (MHRA) will be made separately in keeping with the reliance route under the International Recognition Procedure (IRP).

Dr. Reddy's Receives Positive CHMP Opinion From EMA For Its Proposed Rituximab Biosimilar Candidate DRL_RI

Dr Reddy's Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>) reported quarterly earnings of ₹83.46 per share which beat the analyst consensus estimate of $76.83 by 8.63 percent. This is a 0.9 percent decrease over earnings of ₹84.22 per share from the same period last year. The company reported quarterly sales of ₹76.727 billion which beat the analyst consensus estimate of ₹72.830 billion by 5.35 percent. This is a 13.87 percent increase over sales of ₹67.384 billion the same period last year.

Earnings Beats

Dr Reddy's Laboratories Q1 2025 GAAP EPS ₹83.46 Beats ₹76.83 Estimate, Sales ₹76.727B Beat ₹72.830B Estimate

Dr. Reddy's Signs Non-Exclusive Patent Licensing Agreement With Takeda To Commercialize Vonoprazan In India

Dr Reddy's Laboratories ( ($RDY) ) just unveiled an announcement. Dr. Reddy's Laboratories has announced that its Board of Directors will meet on J...

Dr. Reddy's Laboratories Announces Board Meeting for Financial Results Review

Dr Reddy's Laboratories ( ($RDY) ) just unveiled an update. Dr. Reddy's Laboratories has announced the incorporation of a new wholly-owned subsidia...

Dr. Reddy's Laboratories Expands European Footprint with New Finnish Subsidiary

Dr Reddy's Laboratories ( ($RDY) ) has provided an update. Dr. Reddy's Laboratories announced that ICRA Limited has reaffirmed its credit rating fo...

Dr. Reddy's Laboratories' Credit Rating Reaffirmed by ICRA

Top ranked Indian equities according to SA Quant

An update from Dr Reddy's Laboratories ( ($RDY) ) is now available. Dr. Reddy's Laboratories has announced the sale of its wholly owned subsidiary,...

Dr. Reddy's Sells Non-Strategic Louisiana Subsidiary

Dr Reddy's Laboratories ( ($RDY) ) just unveiled an update. Dr. Reddy's Laboratories Ltd. has announced it will release its financial results for t...

Dr. Reddy's to Announce Q3FY25 Financial Results on January 23, 2025

Bank of America Securities analyst Neha Manpuria maintained a Buy rating on Dr Reddy's Laboratories (RDY – Research Report) today and set a price t...

Dr Reddy's Laboratories (RDY) Gets a Buy from Bank of America Securities

Dr. Reddy's Q3 2025 Earnings Preview

Dr Reddy's Laboratories ( ($RDY) ) has shared an update. In a recent disclosure, Dr. Reddy's Laboratories announced ongoing legal challenges relate...

Dr. Reddy's Laboratories Faces Legal Challenges Over Revlimid® Patent Settlement

Here's the major earnings before the open tomorrow

HYMTF

INDA

INFY

SIFY

YTRA

Press Releases

Dr. Reddy's Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab Biosimilar

Dr. Reddy's Laboratories, Aurigene Pharmaceutical Services, and Kainomyx Announce Potential Partnership for Joint Development of Affordable Anti-Malarial Drug

Dr. Reddy's signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries

Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India's First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma

Market Alert: Dr. Reddy's Labs Reports New Data for Aurigene CAR-T Phase 1, Gets Approvals for Phase 2 Trials Progression

Dr. Reddy's Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month

Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year

Dr. Reddy's Q2 & H1FY25 Financial Results

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market

Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Dr Reddy's Laboratories

Dr Reddy's Laboratories (RDY) 옵션

Dr Reddy's Laboratories (NYSE:RDY) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌